NASDAQ$PSNL
Personalis Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Personalis reported a revenue increase of 12% compared to the same quarter last year, driven by a 50% growth in revenue from oncology customers.
Personalis, Inc. reported financial results for the third quarter ended September 30, 2021, with a revenue of $22.3 million, a 12% increase compared to the third quarter of 2020. The company's revenue from oncology customers grew 50% over the same period last year. Personalis is preparing to launch NeXT Personal, its Minimal Residual Disease (MRD) offering in December.
- Reported quarterly revenue of $22.3 million, a 12% increase year-over-year.
- Revenue from biopharma and all other customers, excluding the VA MVP, reached a record $8.6 million, a 50% increase year-over-year.
- Received a new order from the VA MVP with an aggregate value of approximately $10 million over a six-month period.
- Announced a collaboration with Mayo Clinic to provide clinical-grade comprehensive cancer genomic sequencing for patients.
Headline financials
Revenue & EPS history
Personalis · Revenue · Quarterly
$22.3M
Revenue by segment
Personalis · $18.2M total across 4 segments · Q3 2023
- Pharma tests and services$8M—43.8%
- Enterprise sales$7.81M—42.8%
- Population sequencing$2.4M—13.2%
- Other$38K—0.2%
Forward guidance
Personalis expects total revenue to be in the range of $20.2 million to $20.4 million and net loss to be in the range of $22 million to $23 million for the fourth quarter of 2021. For the full year of 2021, Personalis expects total revenue to be approximately $85 million and net loss to be in the range of $67 million to $68 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+1.5%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+19.9%
Q1 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -0.7% | +76.6% | |
| Q4 2025 | +0.6% | -1.1% | -29.8% | |
| Q3 2025 | -12.3% | -1.1% | +9.5% | |
| Q1 2025 | +19.9% | +27.5% | +30.3% | |
| Q4 2024 | -2.4% | +5.9% | -14.6% | |
| Q3 2024 | -23.4% | -12.8% | -26.4% | |
| Q2 2024 | +7.2% | +34.7% | +67.8% | |
| Q1 2024 | +4.4% | -2.5% | -14.6% | |
| Q4 2023 | +3.3% | +16.0% | -0.7% | |
| Q3 2023 | +10.4% | -3.8% | +39.6% | |
| Q2 2023 | +4.7% | +7.9% | -17.9% | |
| Q1 2023 | +4.5% | +3.2% | -6.4% | |
| Q4 2022 | -7.2% | -5.3% | -18.2% | |
| Q3 2022 | -1.5% | -15.3% | +4.7% | |
| Q2 2022 | +10.6% | +11.1% | -21.4% | |
| Q1 2022 | -7.2% | -24.8% | -34.1% | |
| Q4 2021 | +12.2% | +11.0% | -14.4% | |
| Q3 2021 | +2.6% | -5.4% | -38.9% | |
| Q2 2021 | +10.2% | +4.1% | +12.4% | |
| Q1 2021 | -0.6% | -9.9% | -4.3% | |
| Q4 2020 | -11.1% | -10.8% | -36.3% | |
| Q3 2020 | +0.1% | -0.3% | +13.6% | |
| Q2 2020 | -2.4% | -3.7% | -4.7% | |
| Q1 2020 | +4.6% | +7.2% | +27.6% | |
| Q4 2019 | +17.5% | +27.5% | +52.8% | |
| Q3 2019 | +0.2% | -12.7% | +0.3% | |
| Q2 2019 | -15.6% | -6.2% | -11.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro